What it's for (Indications)
- Drotaverine is a potent antispasmodic agent primarily indicated for the symptomatic treatment of various conditions characterized by smooth muscle spasms.
- This includes spasms of the smooth musculature associated with gastrointestinal diseases such as gastric and duodenal ulcers, gastritis, enteritis, colitis, and irritable bowel syndrome (IBS).
- Furthermore, it is effective in relieving spasms within the biliary tract, exemplified by cholecystolithiasis, cholangitis, cholecystitis, and postcholecystectomy syndrome.
- In the genitourinary tract, drotaverine is used for spasms associated with nephrolithiasis, ureterolithiasis, pyelitis, cystitis, and tenesmus of the bladder.
- It is also clinically utilized for menstrual pain (dysmenorrhea) and as an adjunct in other painful conditions where smooth muscle spasm contributes significantly to the symptomology.
- Its therapeutic role is centered on providing relief from involuntary contractions, thereby alleviating pain and discomfort.
- The specific indications for use should always be determined by a qualified healthcare professional based on the individual patient's clinical presentation and underlying etiology.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of drotaverine must be individualized based on the patient's condition, severity of spasms, and route of administration, always under medical supervision. For adults, the typical oral dosage is 40 to 80 mg, administered two to three times daily. The maximum daily oral dose generally should not exceed 240 mg. For acute and severe cases, drotaverine can be administered parenterally. The usual intravenous (IV) or intramuscular (IM) dose for adults is 40 to 80 mg, which may be repeated one to three times daily, with a maximum daily parenteral dose of 240 mg. When given intravenously, it should be administered slowly to minimize the risk of adverse effects, particularly hypotension. In pediatric populations, the dosage is significantly lower and must be carefully calculated based on age and weight, typically not recommended for infants under 1 year of age. Adjustment of dosage may be necessary in patients with hepatic or renal impairment, although caution is generally advised or contraindication may apply in severe cases. Adherence to prescribed dosages and administration routes is crucial to ensure efficacy and minimize potential risks. |
Safety & Warnings
Common Side Effects
- Like all medications, drotaverine can cause side effects, although not everyone experiences them.
- Common side effects are generally mild and transient, including headache, dizziness, nausea, constipation, and palpitations.
- Less commonly, patients may experience allergic reactions such such as rash, urticaria, angioedema, or pruritus, which necessitate immediate discontinuation of the drug and medical attention.
- More serious, but rare, cardiovascular effects can occur, particularly with rapid intravenous administration, including a significant drop in blood pressure (hypotension), tachycardia, and in very rare instances, collapse.
- Other reported side effects include insomnia, anxiety, vertigo, and vomiting.
- In isolated cases, local reactions at the injection site (e.
- g.
- , pain, swelling) have been reported for parenteral administration.
- Patients should be advised to report any persistent or bothersome side effects to their healthcare provider.
- The risk-benefit profile should always be considered, especially in patients with pre-existing conditions or those receiving concomitant medications.
Serious Warnings
- Black Box Warning: **Serious Warnings**: Drotaverine is not approved by the U.S. Food and Drug Administration (FDA) for use in the United States, and consequently, does not carry an FDA-mandated Black Box Warning. While widely utilized in other countries, its safety and efficacy profile have not been established under stringent FDA regulatory standards. Patients should be explicitly aware of this regulatory status. Significant caution is paramount for individuals with severe underlying medical conditions. Drotaverine is strictly contraindicated in patients with severe hepatic, renal, or cardiac insufficiency (e.g., severe heart failure, advanced AV block) due to the heightened risk of drug accumulation, severe adverse reactions, and potential for exacerbation of these life-threatening conditions. Furthermore, rapid intravenous administration of drotaverine carries a substantial risk of profound and symptomatic hypotension, which can lead to cardiovascular collapse, particularly in patients with pre-existing low blood pressure or compromised cardiovascular status. Close monitoring of vital signs, especially blood pressure, is imperative during and after parenteral administration. The potential for serious cardiac adverse events, though rare, necessitates careful consideration in patients with known cardiovascular disease. Healthcare providers must conduct a thorough risk-benefit assessment and consider alternative treatments, particularly in vulnerable populations, and ensure patients are fully informed of these serious safety concerns and the lack of U.S. FDA approval.
- Drotaverine should be used with caution in certain patient populations and clinical situations.
- Patients with pre-existing hypotension should be closely monitored, as the drug can further lower blood pressure, especially with parenteral administration.
- Individuals with a history of cardiac conditions, including arrhythmias, should receive drotaverine with careful consideration due to the potential for cardiac effects.
- Caution is also warranted in patients with severe hepatic or renal impairment, as drug accumulation may occur, increasing the risk of adverse effects; these conditions are often absolute contraindications in their severe forms.
- The safety of drotaverine in pregnancy and lactation has not been definitively established through adequate and well-controlled human studies, and therefore, its use during these periods should be undertaken only if the potential benefits clearly outweigh the potential risks to the fetus or infant.
- Patients should be advised against driving or operating heavy machinery if they experience dizziness or vertigo after administration.
- Co-administration with levodopa should be avoided as drotaverine may reduce its antiparkinsonian effect.
- Any signs of hypersensitivity reactions require immediate discontinuation of treatment.
How it Works (Mechanism of Action)
Drotaverine exerts its antispasmodic effect by directly influencing the smooth muscle cells. Its primary mechanism of action involves the selective inhibition of phosphodiesterase-4 (PDE4), an enzyme predominantly found in smooth muscle. By inhibiting PDE4, drotaverine prevents the hydrolysis of cyclic adenosine monophosphate (cAMP) into inactive 5'-AMP. This leads to an increase in intracellular cAMP concentrations. Elevated cAMP levels activate protein kinase A (PKA), which subsequently phosphorylates various proteins involved in smooth muscle contraction. Specifically, PKA activation leads to the phosphorylation of myosin light chain kinase (MLCK), reducing its affinity for Ca2+-calmodulin and thereby inhibiting its activity. This reduction in MLCK activity results in decreased phosphorylation of myosin light chain, which is crucial for smooth muscle contraction. Consequently, the smooth muscle relaxes. Unlike anticholinergic antispasmodics, drotaverine acts directly on the smooth muscle cell, providing a more targeted antispasmodic effect with a lower incidence of anticholinergic side effects.